Castle Biosciences

CSTL

Market cap $1.15B

Castle Biosciences (CSTL) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

CSTL, IDN, PANL, FSRL and PRM are showing sharp price strength amid renewed Wall Street volatility.

FRIENDSWOOD, Texas, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has been recognized by the Houston Chronicle as a Houston Top Workplace, which celebrates people-focused, standout workplace cultures. This marks the fifth consecutive year the Company has been ranked among the Houston metro area's esteemed workplaces.

Four rising cash-flow stocks, including PRM, TILE, CSTL and GLDD, stand out with upgraded earnings estimates and strong VGM scores.

Castle will present new data showing the clinical value of DecisionDx-Melanoma in improving sentinel lymph node biopsy decision making at Dermato-Onco2025.

Castle Biosciences' executive management will present a company overview at the Piper Sandler 37th Annual Healthcare Conference on 12/2/25 at 1:10pm ET

Four stocks, CSTL, PRM, SABK and ATRO show recent gains, signaling potential momentum plays for investors in 2025.

Castle Biosciences (CSTL) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Castle Biosciences (NASDAQ:CSTL) rallied more than 20% after delivering a strong Q3 performance. When analyzed through the lens of the Adhishthana Principles, the stock shows clear signs of momentum building.

Castle Biosciences, Inc. (CSTL) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to earnings of $0.08 per share a year ago.